Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Menthol→

Menthol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
89-78-1
Molecular formula
C10H20O
Molecular weight
156.2652 g/mol
Drug class
Topical counterirritanttransient receptor potential melastatin 8 (TRPM8) agonist
Mechanism of action
Activates TRPM8 cold-sensing ion channels in cutaneous sensory neurons, producing a cooling sensation and counterirritant effect that can temporarily reduce perception of superficial pain or itching. Additional effects on sensory signalling depend on concentration and formulation.
Indications / reported uses
  • Temporary relief of minor muscle and joint aches and pains in topical external analgesic preparations
  • Symptomatic relief of minor throat irritation or cough in selected lozenges and topical preparations; route and formulation-specific labels apply
View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Menthol Environmental Risk Assessment (ERA) (the Menthol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.